Samsung Biologics participated in BioProcess International 2025 in Boston from September 15 to 18.
At booth #1010, the company highlighted its end-to-end CDMO capabilities and enhanced service offerings to support diverse pipelines. Earlier this year, Samsung Biologics began operations at its newest Plant 5 and launched ADC manufacturing and development services at its dedicated facility. The company also introduced Samsung Organoids, drug screening services to support accelerated drug discovery and development.
Samsung Biologics also hosted a speaking session on streamlining drug development and presented a poster on analytical method co-qualification.
On the sidelines of BPI 2025, the company’s Sales Team is also in the Boston area for the week to discuss biopharma innovations and collaborative opportunities with existing and potential clients.
To get in touch, visit Contact Us | Samsung Biologics.
Samsung Biologics participated in BioProcess International 2025 in Boston from September 15 to 18.
At booth #1010, the company highlighted its end-to-end CDMO capabilities and enhanced service offerings to support diverse pipelines. Earlier this year, Samsung Biologics began operations at its newest Plant 5 and launched ADC manufacturing and development services at its dedicated facility. The company also introduced Samsung Organoids, drug screening services to support accelerated drug discovery and development.
Samsung Biologics also hosted a speaking session on streamlining drug development and presented a poster on analytical method co-qualification.
On the sidelines of BPI 2025, the company’s Sales Team is also in the Boston area for the week to discuss biopharma innovations and collaborative opportunities with existing and potential clients.
To get in touch, visit Contact Us | Samsung Biologics.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article